Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Cor4.5
Cordyceps – Forschung
Hilft wahrscheinlich
47 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Cordyceps scheint in 9 von 9 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 78 Teilnehmenden.
Basierend auf 47 Studien · 8 Meta-Analysen · 22 RCTs · 11,856 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
9geholfen· 38 weitere ohne bewertete Effektdaten
Nach Outcome
Kidney & renal health
Hilft wahrscheinlich9 Studien
Endurance & exercise performanceKann die Sauerstoffverwertung und VO2 max verbessern · 2-4 weeks · Verbessert VO2 max und Zeit bis zur Erschöpfung in Studien · 3-6 weeks
Hilft wahrscheinlich9 Studien
Immune supportImmunmodulatorische Polysaccharide verstärken die Aktivität von NK-Zellen · 4-8 weeks
Überwiegend Mechanismus / Beobachtung9 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung6 Studien
Anemia & hematology
Überwiegend Mechanismus / Beobachtung4 Studien
Respiratory & lung
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Lean body mass & muscle growth
Zu wenige bewertete Studien2 Studien
Inflammation
Zu wenige bewertete Studien2 Studien
Cognitive function
Zu wenige bewertete Studien1 Studie
Vision & eye health
Zu wenige bewertete Studien1 Studie
Depression & mood
Zu wenige bewertete Studien1 Studie
Skin health
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 26 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
33%
über Studien hinweg
Untersuchte Personen
12k
typische Studie: 78 Personen
Stärkste Designs
30
8 gepoolt, 22 randomisiert
Zeigte Nutzen
100%
9/9 Studien
Wie lange Studien liefen
1–4 Wochen
1
1–3 Monate
6
3+ Monate
1
Untersuchte Populationen
Chronic kidney disease patients2
General population2
Recreational athletes2
Lung cancer patients1
Aktives Forschungsgebiet
30 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
200520152026
1Tumor response rate improvementMeta-AnalyseCited 11×n=928 · large study2024
Compared with conventional treatment, adjuvant treatment with CS of lung cancer not only improve TRR, QOL and immune function, but also reduce the incidence of ADRs and radiation pneumonitis.
Wang C et al. · Journal of ethnopharmacology (2024)
Compared with conventional treatment, adjuvant treatment with CS of lung cancer not only improve TRR, QOL and immune function, but also reduce the incidence of ADRs and radiation pneumonitis.
The optimal usage may be 6 g/d and 21 days/3 to 4 cycles.
2Serum creatinine decreaseMeta-AnalyseCited 51×n=1,746 · large study2014
We found that Cordyceps preparation, as an adjuvant therapy to conventional medicine, showed potential promise to decrease serum creatinine, increase creatine clearance, reduce proteinuria and alleviate CKD-associated complications, such as increased haemoglobin and serum albumin.
Zhang HW et al. · The Cochrane database of systematic reviews (2014)
We found that Cordyceps preparation, as an adjuvant therapy to conventional medicine, showed potential promise to decrease serum creatinine, increase creatine clearance, reduce proteinuria and alleviate CKD-associated complications, such as increased haemoglobin and serum albumin.
However, definitive conclusions could not be made because of the low quality of evidence.
3Diabetic kidney disease progressionMeta-AnalyseCited 16×n=4,288 · very large study2015
However, with regard to low-quality and significant heterogeneity of included trials, to further verify the current results from this meta-analysis, long-term and well-designed RCTs with high-quality study are warranted to ascertain the long-term efficacy of O. sinensis.
Luo Y et al. · Renal failure (2015)
However, no effects were found for DBP, FBG, and HbA1C.
However, with regard to low-quality and significant heterogeneity of included trials, to further verify the current results from this meta-analysis, long-term and well-designed RCTs with high-quality study are warranted to ascertain the long-term efficacy of O. sinensis.
4Safety and efficacy of fungi-based bioproductsSystematische ÜbersichtCited 2×n=134 · medium study2025
In future research, the development of integrated guidelines that simultaneously consider human, animal, and environmental health is recommended.
de Sousa TK et al. · Pathogens (Basel, Switzerland) (2025)
A total of 134 articles were selected: 84 bioassay articles (63%), 36 case reports (27%), 10 field studies (7%), and 4 other types of studies (3%).
Nevertheless, the necessity for standardized safety assessments is emphasized.
In order to ensure greater effectiveness, it is essential to develop unified protocols and bioassays with specific risk indicators aligned with the One Health approach.
5BODE IndexSystematische ÜbersichtCited 27×n=1,834 · large study2014
These issues should be addressed in future trials.
Chen X et al. · PloS one (2014)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The main meta-analysis results showed relative benefits for BODE Index in nine studies (mean difference [MD] -0.71, 95% confidence interval [CI] -0.94, -0.47) and 6MWT/D in 17 studies (MD 54.61 meters, 95%CI 33.30, 75.92) in favour of the CHM plus RP groups.
Detailed sub-group and sensitivity analyses were conducted.
Clinically meaningful benefits for BODE Index and 6MWT were found in multiple studies.
6Serum creatinine improvementMeta-Analysen=655 · large study2019
Given the small number of trials included, the unclear methodological quality of the included trials, and the high heterogeneity in pooled analyses, the evidence obtained in this review is insufficient to recommend the use of cordyceps as adjunctive treatment in hemodialysis patients.
Bee Yean O et al. · Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2019)
However, there was no significant improvement for serum creatinine and low-density lipoprotein cholesterol.
Given the small number of trials included, the unclear methodological quality of the included trials, and the high heterogeneity in pooled analyses, the evidence obtained in this review is insufficient to recommend the use of cordyceps as adjunctive treatment in hemodialysis patients.
Further research warranted to confirm findings
7Antidepressant mechanisms of edible and medicinal fungiSystematische ÜbersichtCited 8×2025
Future research should address these gaps, emphasizing personalized interventions and advanced technologies for next-generation antidepressant foods.
Gong P et al. · Molecular nutrition & food research (2025)
Additionally, it discusses the use of EMFs in functional foods and dietary supplements, innovations like 3D food printing for depression-related issues, and synthetic biology for enhancing compound production.
Artificial intelligence is used to model complex mechanisms.
However, challenges remain, such as standardization and lack of clinical validation.
8Patient survival and graft functionMeta-AnalyseCited 14×n=447 · medium study2015
Although there were some favourable aspects associated with Cordyceps, longer-term studies are needed to clarify any benefit-harm trade-off.
Hong T et al. · The Cochrane database of systematic reviews (2015)
Anaemia, leucopenia, and liver function improved, and incidence of infection may also be reduced.Compared with low dose CsA versus standard dose CsA, Cordyceps did not demonstrate any statistically significant differences in patient survival, graft loss, acute rejection or allograft function.
Although there were some favourable aspects associated with Cordyceps, longer-term studies are needed to clarify any benefit-harm trade-off.
Future studies should investigate the use of Cordyceps in combination with other immunosuppressive agents such as tacrolimus, mycophenolate mofetil or induction therapy.
9FEV1 and respiratory function improvementMeta-AnalyseCited 5×2024
Bailing capsules have shown promising results in the treatment of stable COPD.
Ma G et al. · Pharmaceutical biology (2024)
The meta-analysis of 27 RCTs showed significant improvements in the treatment group for forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, and the 6-min walk test (6MWT).
Bailing capsules have shown promising results in the treatment of stable COPD.
Future studies should focus on large-scale, multicenter RCTs to confirm the long-term benefits and safety of Bailing capsules.
This systematic-review examined the effects of Cordyceps.
Kanubaddi K, Yaung C, Harn H, Chiou T, Hsu S, Wijaya I, Lin S, Wuli W. · International journal of molecular sciences (2026)
Systematic review examining Cordyceps efficacy
Published in International journal of molecular sciences (2026)
Further research warranted to confirm findings
12Systematische Übersichtn=194 · medium study2026
The paper would provide evidence for clinical use of Cordyceps and lay a foundation for its future development.
Zhang W, Zong Y, Huang X, Zheng J, Shan J, Di L. · Phytotherapy research : PTR (2026)
Up to now, Cordyceps does not show obvious toxic side effects in preclinical and clinical studies.
Cordyceps is a promising fungal source.
This review comprehensively analyzed the biologically active ingredients and elucidated the underlying mechanisms of Cordyceps in the treatment of respiratory diseases.
Supplementary information The online version contains supplementary material available at 10.1007/s13197-025-06531-5.
Parthasarathy S, Tharumasivam SV, Aly SH, Giridharan B, Durairaj S, Elbadry AMM, El-Shazly M. · Journal of food science and technology (2026)
However, more research is needed to understand C. militaris' mechanisms of action and confirm its efficacy in health applications.
Safety, quality considerations, dosage recommendations, and potential interactions with other supplements or medications are also discussed.
Overall, C. militaris mushroom holds significant promise as a multiphase dietary supplement, but careful evaluation and consultation with healthcare professionals are advised for optimal use.
Well-designed randomized controlled trials using chemically characterized preparations and homogeneous athletic populations are required to clarify the efficacy and practical relevance of C. militaris in sports nutrition.
Jędrejko M et al. · Nutrients (2026)
Several studies also evaluated biochemical markers related to muscle damage and inflammatory responses, including creatine kinase, blood urea nitrogen, and white blood cell counts.
Although some studies reported improvements in selected performance and recovery parameters, the findings were inconsistent.
Well-designed randomized controlled trials using chemically characterized preparations and homogeneous athletic populations are required to clarify the efficacy and practical relevance of C. militaris in sports nutrition.
The purpose of the present review is to investigate the pharmacological properties of W. somnifera and Cordyceps species in the context of AD treatment and explore the therapeutic potential of the constitutive bioactive molecules in preclinical models mimicking this neurodegenerative condition.
Tancreda G, Tancreda G, Ravera S, Panfoli I. · International journal of molecular sciences (2025)
It contains several ergostane-type steroidal lactones-such as withanolides and withaferin A-and various alkaloids, contributing to its antioxidant and neuroprotective effects.
Likewise, cordycepin is the main bioactive principle found in Cordyceps fungi .
This natural nucleoside has been reported to possess therapeutic potential as an anti-cancer, immunomodulatory, and anti-inflammatory agent, with some studies suggesting a beneficial role in AD treatment.
Yang EJ et al. · Phytotherapy research : PTR (2025)
This study reviewed recent and notable literature evaluating the immunomodulatory potentials of CM extract, cordycepin, and polysaccharides.
In vitro, in vivo, and clinical trial results indicate that CM is safe for administration and shows promise for developing functional foods having various efficacies such as immunomodulation, anti-tumor, and neuroprotection.
YChCC represent a promising adjuvant therapy for patients with stable COPD, ranging from mild to severe.
Li S et al. · Journal of evidence-based medicine (2025)
Compared with BLC, YChCC significantly reduced the number of acute exacerbations (FAS: p = 0.002; PPS: p = 0.003) and prolonged time to first exacerbation.
YChCC represent a promising adjuvant therapy for patients with stable COPD, ranging from mild to severe.
They significantly prolong the time to the first acute exacerbation and reduce the frequency of acute exacerbations, thereby offering potential benefits in managing COPD.
Therefore, C. cicadae mycelium supplementation may be used for dry eye alleviation as a novel therapeutic intervention.
Chang HH et al. · International journal of medicinal mushrooms (2022)
Dry eye disease (DED), a multifactorial inflammatory ocular surface disorder, affects up to 50% of individuals over 50 years old worldwide and is one of the most common reasons for seeking ophthalmologic care.
The results showed a significantly increased TBUT as well as a significant decrease in tear osmolarity, in parallel with the decrease of tear electrolytes, especially Na+ and Cl ions.
Although significant increase of tear volume was not observed, the increased TBUT suggests mitigation of dry eye through improvement of tear quality.
20Melasma severity (MASI scores)RCTCited 1×n=58 · small study2025
Our study demonstrated that both oral TXA combined with hydroquinone cream and oral TXA combined with Cordyceps essence significantly improved melasma in women.
Shen S et al. · Journal of cosmetic dermatology (2025)
Borderline
After 12 weeks of treatment, intra-group comparisons revealed that MASI scores, MI, and EI significantly decreased in both Group A and B compared to baseline (p < 0.05).
Adverse reactions occurred in 4 people (13.8%) in Group A and 1 person (3.3%) in Group B.
Our study demonstrated that both oral TXA combined with hydroquinone cream and oral TXA combined with Cordyceps essence significantly improved melasma in women.